Comprehensive Pathway Analysis
How InnoSIGN can benefit you
InnoSIGN’s Comprehensive Pathway Analysis (CPA) platform unlocks the true value next generation sequencing (NGS) to revolutionize how patients are diagnosed, stratified, and treated across various diseases.
How InnoSIGN can benefit you
Applicable Diseases
- Oncology
- Auto Immune Diseases
- Metabolic Diseases
Applications
- New patient stratification + subtyping
- Therapy response prediction
- Resistance mechanism identification
- Combination therapy opportunities
- Discovery / preclinical insights
Benefits
- Deeper, more actionable analysis of available patient data (RNA-seq)
- Faster and optimized therapy selection
- Better and more durable patient outcomes
- Reduced wasted spend on failed treatments